GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arqule Inc (NAS:ARQL) » Definitions » Financial Strength

Arqule (Arqule) Financial Strength : 0 (As of Sep. 2019)


View and export this data going back to 1996. Start your Free Trial

What is Arqule Financial Strength?

Arqule has the Financial Strength Rank of 0.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

Arqule did not have earnings to cover the interest expense. Arqule's debt to revenue ratio for the quarter that ended in Sep. 2019 was 20.77. As of today, Arqule's Altman Z-Score is 0.00.


Competitive Comparison of Arqule's Financial Strength

For the Biotechnology subindustry, Arqule's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arqule's Financial Strength Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arqule's Financial Strength distribution charts can be found below:

* The bar in red indicates where Arqule's Financial Strength falls into.



Arqule Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Arqule's Interest Expense for the months ended in Sep. 2019 was $-0.43 Mil. Its Operating Income for the months ended in Sep. 2019 was $-11.28 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2019 was $11.74 Mil.

Arqule's Interest Coverage for the quarter that ended in Sep. 2019 is

Arqule did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

Arqule's Debt to Revenue Ratio for the quarter that ended in Sep. 2019 is

Debt to Revenue Ratio=Total Debt (Q: Sep. 2019 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(5.546 + 11.737) / 0.832
=20.77

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Arqule has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Arqule  (NAS:ARQL) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

Arqule has the Financial Strength Rank of 0.


Arqule Financial Strength Related Terms

Thank you for viewing the detailed overview of Arqule's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Arqule (Arqule) Business Description

Traded in Other Exchanges
N/A
Address
One Wall Street, Burlington, MA, USA, 01803
Arqule Inc is a biopharmaceutical company, engaged in the research and development of therapeutics to treat cancers and rare diseases. The objective of the company is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that will dramatically extend and improve the lives of the patients. These drugs focus on the biological pathways implicated in a range of cancers and certain non-oncology indications. Product portfolios of the group include Tivantinib, ARQ 087, ARQ 092, ARQ 761, and ARQ 751. Geographically, the firm operates through the region of United States.
Executives
Patrick J Zenner director C/O DENDRITE INTERNATIONAL INC., 1405/1425 ROUTE 206 SOUTH, BEDMINSTER NJ 07921
Marc Schegerin officer: CFO and Treasurer ARQULE INC, 1 WALL ST FL6, BURLINGTON MA 01803
Brian Schwartz officer: See Remarks C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Ran Nussbaum director C/O KITE PHARMA, INC., 2225 COLORADO AVENUE, SANTA MONICA CA 90404
Timothy C Barabe director C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Susan L. Kelley director C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Michael D Loberg director C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Paolo Pucci director, officer: Chief Executive Officer C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Merck & Co., Inc. 10 percent owner 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Merck Sharp & Dohme Corp. 10 percent owner ONE MERCK DRIVE, WHITEHOUSE STATION NJ 08889
Robert J Weiskopf officer: Chief Financial Officer C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104